Lorbrena tablets 100mg, with the active ingredient Lorlatinib, is produced by Pfizer. This medicine (YJ code: 4291055F2027, standard: 100mg 1 tablet) is indicated for the treatment of adults with ALK-positive metastatic non-small cell lung cancer (NSCLC).
Lorbrena tablets 100mg
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →